Reaching zero-dose children: local challenges, global lessons

There isn’t one simple solution for identifying and reaching zero-dose children – local contexts require local solutions. 17 July 2025 by JSI Geography, mobility, language, social norms, and political context can often determine who gets vaccinated and who’s left behind. Understanding these local nuances is the essential first step. This was the focus of Gavi’s…

Children growing up without parents are 70% more likely not to have received a single vaccine

Orphans and children with absent parents are at significantly higher risk of missing out on routine immunisation, a new study has found. 17 July 2025 by Joelle Ducharme A child in the streets of Kausa, India. Credit: Gavi/2023/Prakhar Deep Jain A new study led by researchers at the University of Montreal and the University of Minnesota…

Emergency vaccinations cut outbreak deaths by nearly 60%, study finds

A groundbreaking modelling study shows how outbreak response vaccinations have prevented millions of infections and saved billions of dollars in economic losses. 14 July 2025 by Linda Geddes A community health volunteer in Kenya marking a child with a pen after being vaccinated against cholera. Credit: Gavi/2023/Kelvin Juma Emergency vaccination responses to outbreaks have cut…

The Nurse’s Orders: how a student nurse is turning social media into a lifesaving tool

Armed with evidence and a gift for simplifying medical jargon, Meluleki Ndwandwe is on a mission to empower Eswatini’s youth with facts, not fear. 4 July 2025 by Nokukhanya Musi–Aimienoho As the sun rises over Eswatini, 21-year-old nursing student Meluleki Ndwandwe sits, hunched over his desk in his university dorm room, uploading posts to social media.…

Monthly Oral PrEP Candidate MK-8527 Shows Promise in Phase 2 Study

A new once-monthly oral HIV prevention drug, MK-8527, has shown a favorable safety profile and promising pharmacokinetics, according to interim results from a phase 2 study presented on July 14 at the IAS 2025 conference in Kigali (Abstract 6515). In the randomized, double-blind, multicenter trial involving 350 participants—over half of them women—MK-8527 was well tolerated…